Evidence map›Paper›PMID 25943887›Full record

ArticleActa neuropathologica2015

Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy.

Johnathan Cooper-Knock, Adrian Higginbottom, Matthew J Stopford, J Robin Highley, Paul G Ince, Stephen B Wharton, Stuart Pickering-Brown, Janine Kirby, Guillaume M Hautbergue, Pamela J Shaw

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 1 pooled it
13.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 1 synthesis or guideline pooled it, 170 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Targeting GeneInternational journal of molecular sciences · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. ALS' Perfect Storm:Cells · 2024
    Review
  15. Promoters in Pichia pastoris: A Toolbox for Fine-Tuned Gene Expression.Methods in molecular biology (Clifton, N.J.) · 2024
    Review
  16. Article
  17. Article
  18. GActa neuropathologica · 2023
    Article
  19. Article
  20. Journal of personalized medicine · 2023
    Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Johnathan Cooper-KnockSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 385A Glossop Road, Sheffield, S10 2HQ, UK.
Adrian Higginbottom
Matthew J Stopford
J Robin Highley
Paul G Ince
Stephen B Wharton
Stuart Pickering-Brown
Janine Kirby
Guillaume M Hautbergue
Pamela J Shaw
University of Sheffield · GBUniversity of Manchester · GB

Funding

Medical Research Council G0400074Medical Research Council G0502157Medical Research Council G0 800380Medical Research Council G0800380Medical Research Council G0900652Medical Research Council G1100540Medical Research Council MR/K000039/1Medical Research Council MR/K003771/1Medical Research Council MR/L016451/1Motor Neurone Disease Association COOPER-KNOCK/FEB12/942-795Wellcome Trust 089701
6 · The paper itself

Abstract

GGGGCC repeat expansions of C9ORF72 represent the most common genetic variant of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. We and others have proposed that RNA transcribed from the repeat sequence is toxic via sequestration of RNA-binding factors. Both GGGGCC-repeat (sense) and CCCCGG-repeat (antisense) molecules are detectable by fluorescence in situ hybridisation as RNA foci, but their relative expression pattern within the CNS and contribution to disease has not been determined. Blinded examination of CNS biosamples from ALS patients with a repeat expansion of C9ORF72 showed that antisense foci are present at a significantly higher frequency in cerebellar Purkinje neurons and motor neurons, whereas sense foci are present at a significantly higher frequency in cerebellar granule neurons. Consistent with this, inclusions containing sense or antisense derived dipeptide repeat proteins were present at significantly higher frequency in cerebellar granule neurons or motor neurons, respectively. Immunohistochemistry and UV-crosslinking studies showed that sense and antisense RNA molecules share similar interactions with SRSF2, hnRNP K, hnRNP A1, ALYREF, and hnRNP H/F. Together these data suggest that, although sense and antisense RNA molecules might be expected to be equally toxic via their shared protein binding partners, distinct patterns of expression in various CNS neuronal populations could lead to relative differences in their contribution to the pathogenesis of neuronal injury. Moreover in motor neurons, which are the primary target of pathology in ALS, the presence of antisense foci (χ (2), p < 0.00001) but not sense foci (χ (2), p = 0.75) correlated with mislocalisation of TDP-43, which is the hallmark of ALS neurodegeneration. This has implications for translational approaches to C9ORF72 disease, and furthermore interacting RNA-processing factors and transcriptional activators responsible for antisense versus sense transcription might represent novel therapeutic targets.

Indexed as

Amyotrophic Lateral SclerosisC9orf72 ProteinCerebellumDNA-Binding ProteinsDNA Repeat ExpansionFemaleFrontotemporal Lobar DegenerationHippocampusHumansInclusion BodiesMaleMiddle AgedMotor NeuronsProteinsPurkinje CellsRNA, AntisenseC9orf72 ProteinC9orf72 protein, humanDNA-Binding ProteinsProteinsRNA, AntisenseTARDBP protein, human

Identifiers

PMID25943887
PMCPMC4468790
OpenAlexW222561556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.